Navigation Links
Predicting the future in ovarian cancer
Date:11/14/2007

Kisspeptin and its receptor GPR54 predict a favourable clinical outcome in women with ovarian carcinoma, and are specific for the clear cell carcinoma subtype, research published this week in the online open access journal, BMC Medicine, reveals.

The kisspeptins, a family of peptide hormones, and the receptor GPR54 have previously been associated with anti-metastatic activity in certain human tumours. In this study, researchers have shown that kisspeptin and GPR54 are independent prognostic biomarkers specific for ovarian clear cell carcinoma - the first such markers to be identified.

A research team based at the BC Cancer Agency and Vancouver General Hospital, Vancouver, Canada created a tissue microarray - paraffin blocks which allow numerous tissue samples to be analysed simultaneously - from 518 cases of early-stage ovarian carcinoma. They analysed the samples using antibodies against kisspeptin and the G-protein-coupled receptor GPR54. Cases that showed strong staining for either kisspeptin or GPR54 were scored as positive, the rest negative.

The study revealed that patients who were positive for both kisspeptin and GPR54 had a favourable prognosis as compared to those patients who were negative for both kisspeptin and GPR54 cases - both in terms of disease-specific survival and overall survival. Researchers also found that these molecular markers were significantly associated with the clear cell ovarian carcinomas subtype.

Few prognostic or predictive molecular markers for ovarian cancer exist, yet such markers could be vital for the early diagnosis and management of the disease. The authors propose that in the future, serum kisspeptin levels could provide a means to monitor disease activity, and kisspeptins may even have use as therapeutic agentsin women with ovarian clear cell carcinoma. These possibilities require further research, however.

They write: "We anticipate that the strong association of GPR54 an
'/>"/>

Contact: Charlotte Webber
press@biomedcentral.com
44-020-763-19980
BioMed Central
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Blood test takes step toward predicting Alzheimers risk, Stanford researchers find
3. Predicting survival after liver transplantation
4. Campaign for Americas Future Memorandum: Katrina Storm Warning
5. Shipcom Partners With DOKUMENTA for METROs Future Store Initiative
6. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
7. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
8. The Humana Foundation and Libraries for the Future Launch Health Literacy Pilot in Atlanta
9. Divorce foretells childs future care for elderly parent
10. Experts Agree. Ohios Technology Investment Future Looks Bright
11. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...effective against Lennox-Gastaut syndrome , ...ug called Banzel (rufinamide) has been approved as...ilepsy called Lennox-Gastaut syndrome, the U.S. Fo...The approval was based on results of a four-month .... Compared to patients who took a placebo, those w...
(Date:11/21/2008)...PRNewswire-USNewswire/ -- New research at West Vi...s, spitless tobacco product aimed at young adults ...t RJ Reynolds, Camel Snus - touted as a socially a...risingly high levels of nicotine. , , "Came...f products," said Bruce Adkins of the state Divisi...
(Date:11/21/2008)...ewswire-USNewswire/ -- U.S. News & World Repor... (NCQA) ranked BlueChoice(R) HealthPlan of South C...Plans(TM), published in U.S. News & World Repo...ual ranking ranks the nation,s best health plans b...NCQA accreditation scores. NCQA and U.S. News &...
(Date:11/21/2008)...ewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (...s overwhelmingly approved the proposals submitted ...a Pharmaceuticals Industries Ltd. (Nasdaq: TEVA ...whelming support of the transaction by the Barr sh... and CEO. "We are pleased with the progress that w...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...rganization (NACO) of India plans to promote the d...attle against HIV/AIDS//. The third phase of the N...y to be launched in April. Statistics show that ...the private sector for outpatient care and over 50...
...fusal of surgery to known smokers is all set to be...ating the issue in this week’s BMJ//. The issue wa...t last year to remove smokers from the waiting lis...Peters who is from Concord Repatriation General Ho...
...on therapy on the exterior along with radiation se...highly effective// for treatment of prostate cance...of Radiation Oncology Biology Physics has revealed...undergone such a combination therapy have been com...
...or Disease Control and Prevention (CDC) Atlanta's ...is time the US changed its guidelines// and made T...irrespective of how long they have been residing t...ated if all foreign-born residents from high-risk ...
Other Medicine News:Health News:Refusal of Surgery for Smokers – To Be or Not to Be 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
(Date:11/21/2008)...England, November 21 , ...an Committee for Medicinal Products for Human Use ...n for the approval of Enbrel(R),(etanercept) as a...,adolescents with severe plaque psoriasis. If appr...mmittee,s recommendation, Enbrel will become the,...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Firs...unced that the United States Food and Drug Adminis...MACTA(R) (eltrombopag) for the treatment of thromb...thic) thrombocytopenic purpura (ITP) who have had ...oglobulins or splenectomy. The approval is a signi...
(Date:11/20/2008)...lif., Nov. 20 Duska Ther...nced today that it has submitted its,pivotal Phas...r a Special,Protocol Assessment (SPA) procedure w..., Subject to securing an agreement with the...tive, double-blind, placebo-controlled and randomi...
(Date:11/19/2008)...O, Nov. 19 Posit Science Corporati...the Society for Neuroscience,Annual Conference in...e,training may benefit Baby Boomers. The compute...m (TM) uses adaptive exercises that target auditor...ed to drive generalized,improvements in cognition...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pregnant mice block out unwelcome admirers to protect their pups 4122 1Pregnant mice block out unwelcome admirers to protect their pups 4122 2Capella University Launches Online PhD Specialization in Nursing Education 24214 1Capella University Launches Online PhD Specialization in Nursing Education 24214 2Capella University Launches Online PhD Specialization in Nursing Education 24214 3Incidence of Mantle Cell Lymphoma on Rise 24211 1Incidence of Mantle Cell Lymphoma on Rise 24211 2Breast Fed Babies Have Fewer GI Infections 24208 1Breast Fed Babies Have Fewer GI Infections 24208 2
...roach to Address Growing Problem of Antibiotic Res...ER, British Columbia, March 26, 2007 /PRNewswire/ ... IDR-1 is the first,immune system trigger to cure ...ccording to a paper published in the April 2007,is...ghlights the work of Inimex and its,co-founders Dr...
...rial Shows CRESTOR Slowed Progression Of Atheroscl...sease , LONDON, March 26, 2006-AstraZeneca today a... is the first study to show a,positive effect on a...id artery disease and at low risk of coronary hear...uvastatin) 40mg and presented at,56th Scientific S...
Other Medicine Technology:Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 3First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 4First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 5
Grafton DBM Matrix PLF is the first bone graft material designed specifically for posterolateral fusion procedures. Unique trough-like design allows for easy use with allograft/autograft bone. Demine
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%.
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%.
Inductive demineralized bone matrix and conductive cancellous chips. DBM and cancellous chips will be free of foreign matter. Demineralized bone matrix particle size is 125 to 1000 . Cancellous chip
Medicine Products: